Today Savara Inc. (SVRA) Stock Reaches All-Time Low

The stock of Savara Inc. (NASDAQ:SVRA) reached all time low today, Aug, 14 and still has $2.21 target or 4.00 % below today’s $2.30 share price. This indicates more downside for the $86.76M company. This technical setup was reported by Barchart.com. If the $2.21 PT is reached, the company will be worth $3.47 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 2.95% or $0.07 during the last trading session, reaching $2.3. About 203,128 shares traded. Savara Inc. (NASDAQ:SVRA) has declined 77.34% since August 14, 2018 and is downtrending. It has underperformed by 77.34% the S&P500.

More notable recent Savara Inc. (NASDAQ:SVRA) news were published by: Nasdaq.com which released: “Here’s Why Savara Pharmaceuticals Collapsed Today – Nasdaq” on June 13, 2019, also Benzinga.com with their article: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” published on August 06, 2019, Benzinga.com published: “The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes – Benzinga” on June 13, 2019. More interesting news about Savara Inc. (NASDAQ:SVRA) were released by: Globenewswire.com and their article: “Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies – GlobeNewswire” published on February 06, 2019 as well as Nasdaq.com‘s news article titled: “Mid-Day Market Update: Coda Octopus Group Surges After Strong Q2 Results; Arcadia Biosciences Shares Slide – Nasdaq” with publication date: June 13, 2019.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company has market cap of $86.76 million. The Company’s product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. It currently has negative earnings.

Savara Inc. (NASDAQ:SVRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.